Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

types, of which HPV-16 is the most common. In the U.S., these infections are typically discovered through nearly 60 million Pap screens completed each year, at a cost of up to $6 billion. Each year in the U.S., an estimated 1.2 million women are diagnosed with low grade cervical dysplasia (CIN 1), 300,000 with high grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the FDA for the treatment of any type of CIN.

About HspE7:

The company's lead product candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 for multiple indications.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by HPV. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include statements rega
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... Hovione today announced that its API ... passed a pre-approval inspection by the US Food and Drug ... FDA Consumer Safety Officer, Ms. Britanny Terhar , lasted ... July and concluded on the 25 th . The inspection ... guidelines of Good Manufacturing Practices (GMP) and no Form 483 ...
(Date:7/31/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), Gilead (Nasdaq: GILD - Free ... ), AbbVie (NYSE: ABBV - Free Report ) and ... Today, Zacks is promoting its ,Buy, stock recommendations. Get ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... MADISON, N.J. and AUSTIN, Texas, May 24, 2011 ... Obstetrics & Gynecology demonstrated that adding OVA1 to ... would identify more ovarian cancers than a physician,s preoperative ... this month in the journal, which is the official ...
... May 24, 2011 The Board of Directors of BD (Becton, ... quarterly dividend of 41 cents per common share, payable on June ... indicated annual dividend rate is $1.64 per share. ... leading global medical technology company that develops, manufactures and sells medical ...
Cached Medicine Technology:OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 2OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 3OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 4
(Date:8/1/2014)... Fitness is something most people can add ... around the block to biking ten or more miles, adding ... maintain throughout the year. The Forbes Living talk show ... will feature special guests, tips to get started and cool ... series will air on most popular cable television networks. ...
(Date:8/1/2014)... Online retailer Disposable Medical Express has ... guarantee on their inventory of Tranquility incontinence care products. ... pads along with other personal care products. , ... a line of incontinence products that you love,” a ... works for you, you shouldn't have to compromise because ...
(Date:8/1/2014)... 01, 2014 We are very ... on AWS Marketplace. EspressReport ES-AMI delivers enterprise grade ... $0.50 per hour (AWS infrastructure charges apply). , ... enterprise BI and operational reporting system with strong ... ad hoc reporting. It allows users to easily ...
(Date:8/1/2014)... Stress management can be difficult in this day and ... diminish rest and leisure time, stress can mount up and ... a way to manage stress in order to be healthy ... good sense of work-life balance is the key to managing ... of SF Custom Chiropractic. “Stress, left unchecked, can not only ...
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Register to ... one of the most active years on record for life ... in life sciences represented 22 percent of all venture dollars ... exits and achieved high valuations. , However, 2014 is ... a recent report by Silicon Valley Bank, while life sciences ...
Breaking Medicine News(10 mins):Health News:Forbes Living to Air Fitness Forward Series 2Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
... the Prime Minister, Premiers and Chief Ministers urging the ... and childcare workers are trained in recognizing and handling ... COAG also should ensure the provision of legal immunity ... severe allergic reactions. ,'Greater awareness and ...
... says that Tai Chi, may be helpful in preventing ... been found not only to increase// the immunity to ... to varicella vaccine as well. ,This National ... clinical trial to suggest that a behavioral intervention, alone ...
... in Mumbai will soon start an integrated trauma care facility ... to patients on way to a hospital from an accident ... Physicians of Indian Origin (AAPI), the emergency medical service and ... within minutes of an accident. ,"The ambulance would ...
... Radiologists using computer-aided detection software for mammograms are more ... than "human reviewers using// their eyes and experience," and ... to a study. ,CAD systems use complex ... a radiologist to review. The systems, which cost $50,000 ...
... - supporting research and providing education, advocacy and ... - today said physicians should consider lowering the ... with multiple myeloma. ,High dose dexamethasone ... treatment of myeloma alone and in combination with ...
... McGill University in Montreal in Canada have found that by ... alter the speed with which the mice// learned to perform ... develop drugs to improve memory. ,The finding paves ... loss and dementia, but similar drugs might also improve the ...
Cached Medicine News:Health News:COAG Must Make Combating Severe Allergies A National Priority 2Health News:Tai Chi may Be Useful to Prevent Shingles in Older Adults 2Health News:Mumbai to Have Integrated Trauma Care Facility 2Health News:Mumbai to Have Integrated Trauma Care Facility 3Health News:New Clinical Trial Results Could Improve Survival for Myeloma Patients 2Health News:New Clinical Trial Results Could Improve Survival for Myeloma Patients 3Health News:Canadian Researchers Raise Hopes of Treatment for Memory Loss 2
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
... hinged knee brace provides maximum ... types of sports and activities. ... rubber pads to support medial ... buttress and hyperextension stop. 3/16" ...
Medicine Products: